Articles from Sensus Healthcare, Inc.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces it will be showcasing its full line of commercial Superficial Radiotherapy (SRT) products including the SRT-100®, SRT-100+ and SRT-100 Vision™ systems, along with several innovative pre-commercial products, at the 2025 American Academy of Dermatology (AAD) Annual Meeting taking place March 7-11, 2025 at the Orange County Convention Center in Orlando, Florida.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces the publication of a study titled "Keloid Excision With Primary Closure Combined With Superficial Radiation Therapy (SRT-100)" in the Annals of Plastic Surgery.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the company has resumed purchasing shares of its common stock in open-market transactions under a $3.0 million share repurchase program approved by its Board of Directors and announced in August 2023.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and 12 months ended December 31, 2024.

Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced its participation in The Microcap Conference 2025 being held January 28-30, 2025, in Atlantic City, N.J.

Full-service medical oncology practice to pioneer the use of SRT to treat companion animals for both home and veterinary clinic visits

BOCA RATON, Fla., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 14, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Continues customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancers

BOCA RATON, Fla. , Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

BOCA RATON, Fla., July 25, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

First veterinary commercial sale of the SRT-100 outside the U.S.

Reminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024

BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones. 

BOCA RATON, Fla. , April 18, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Management will discuss its new “Fair Deal Agreement” for its SRT-100 Vision™ IG-SRT in one-on-one meetings in Dana Point, California on March 18th and 19th

  New shared service contract expands the unmatched clinical results achieved with IG-SRT to a broader base of prospective customers

BOCA RATON, Fla., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that the U.S. Patent and Trademark Office (USPTO) has issued Patent No. 11,894,123 B2, titled “Radiotherapy Mobile and Wireless Device Workflow Management System.” 

Physician-run radiation oncology innovator also to research new indications and broaden the market for SRT to include inflammatory diseases

BOCA RATON, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Samuel O’Rear will not stand for reelection to the Company’s Board of Directors at the Company’s 2024 annual meeting of stockholders.  Mr. O’Rear has been a Director of Sensus Healthcare since 2012.

BOCA RATON, Fla. , Jan. 30, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 8, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Ships more than 60 SRT units in 2023To report full financial results and hold conference call on February 8th

BOCA RATON, Fla, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 9, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the third quarter of 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

BOCA RATON, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that management will deliver a company presentation and hold investor meetings at the Roth MKM 2023 Healthcare Opportunities Conference being held October 12, 2023 in New York City. Sensus management will also participate in the 43rd Annual Fall Clinical Dermatology Conference being held October 19-22, 2023 at the Wynn Hotel in Las Vegas.

Continues SRT-100+™ customer expansion to hospital oncology departments for the outpatient treatment of non-melanoma skin cancers

BOCA RATON, Fla, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces its participation in the American Society for Radiation Oncology (ASTRO) Annual Meeting to be held in San Diego from October 1-4. Leveraging this esteemed event, Sensus Healthcare is set to present its full line of state-of-the-art superficial radiotherapy (SRT) devices for the treatment of non-melanoma skin cancer and keloids to hospital administrators and radiation oncologists from around the world.

BOCA RATON, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that its Board of Directors has authorized a new share repurchase program under which the Company may repurchase up to $3.0 million of its common stock.

BOCA RATON, Fla., July 26, 2023 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 3, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Delivery of the SRT-100 marks the expansion of radiotherapy services at Dublin’s Beacon Hospital

Full line of Sensus’ SRT products for the non-invasive treatment of non-melanoma skin cancer and keloids now available to MIS Healthcare customers

BOCA RATON, Fla, June 15, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces its participation in the Maxim Group Virtual Healthcare Conference hosted by M-Vest.  Joe Sardano, Chairman and Chief Executive Officer, Michael Sardano, President and General Counsel, and Javier Rampolla, Chief Financial Officer, will be featured on the Aesthetics Industry Panel, taking place from 12 noon to 1:00 p.m. Eastern time on Tuesday June 20, 2023.  The panel will be moderated by Maxim Group Executive Managing Director of Research Anthony V. Vendetti.  

BOCA RATON, Fla, May 17, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare Inc. (Nasdaq:SRTS), the leading manufacturer of advanced medical devices for non-surgical skin cancer and keloid scar treatment, is announcing that its superficial radiation therapy SRT-100 system has shown promising results treating Cutaneous Mast Cell Tumors (MCTs) in pets. This new limited study, just published in the Journal of the American Veterinary Medical Association, demonstrates the potential effectiveness and safety of SRT treatment.

BOCA RATON, Fla. , April 25, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Wednesday, May 3, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2023. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

New comprehensive asset and EMR management feature allows users to collect real-time information from the device to manage and maintain multiple machines with Chat GPT

BOCA RATON, Fla., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, February 9, 2023 at 4:30 p.m. Eastern time to discuss the financial results for the fourth quarter and full year 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

BOCA RATON, Fla, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, is pleased to announce the following promotions and appointments to its management team:

Fourth quarter revenues to exceed $13 million; full year revenues to exceed $44 million, representing growth of 60%

BOCA RATON, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, November 3, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the third  quarter of 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones.

Only portable hair removal laser system with blended wavelengths for all skin phototypes to be launched at the Fall Clinical Dermatology Conference

BOCA RATON, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of 10 Transdermal Infusion Systems™ to Hair Enhancement Centers (HEC), a rapidly-growing chain of Texas-based hair loss treatment centers. The Systems will be used to non-invasively deliver U.SK Under Skin’s hair-health serum Skin Savers Hair™.  U.SK Under Skin is a subsidiary of privately-held EMS Pharma, the largest pharmaceutical company in Brazil and itself a subsidiary of Grupo NC, one of Brazil’s largest conglomerates.

BOCA RATON, Fla., July 26, 2022 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 4, 2022 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2022. In addition, management will provide a business update and a discussion on recent and upcoming milestones.